New Autism Therapy Shows Surprising Benefits Even in Adult Mice

Research has challenged the notion that neurological disorders are a product of early developmental failures by investigating autism therapy. A recent study on mice has demonstrated remarkable benefits from a new treatment targeting a specific glycine transporter, raising hopes for more effective interventions in adults with autism.

The breakthrough centers around a receptor known as Slc6a20a/SLC6A20, which plays a crucial role in communication between brain cells. In autism spectrum disorder (ASD), reduced function of this NMDA receptor has been linked to various symptoms, including social and communication difficulties. The study focused on using antisense oligonucleotides (ASOs) to reduce the expression of Slc6a20a, effectively reducing the activity of the glycine transporter.

The results were astonishing. In mouse models with autism-related mutations, treatment with ASO restored NMDA receptor function and significantly improved behavioral deficits associated with ASD. Notably, these benefits persisted in adult mice, challenging the conventional wisdom that the brain is no longer receptive to treatment after major stages of development are complete.

This research has implications extending far beyond autism. Reduced NMDAR activity has been implicated in a range of neurological conditions, including schizophrenia and certain forms of intellectual disability. The discovery of Slc6a20a as a therapeutic target may offer a more targeted approach to treating these disorders, reducing the risk of unwanted side effects associated with earlier strategies.

Human brain organoids created using CRISPR gene editing showed similar results when treated with an ASO targeting the human SLC6A20 gene. This finding suggests that the approach may have relevance for people, offering hope for those living with conditions characterized by NMDAR dysfunction.

The effectiveness and safety profile of this treatment are also noteworthy. A single administration was found to remain effective for at least eight weeks, with no detectable adverse effects observed in treated mice during this period.

This study joins a growing body of research indicating that the brain remains more malleable than previously thought, even into adulthood. The possibility of developing targeted therapies for neurodevelopmental and neuropsychiatric disorders has significant implications for our understanding of brain plasticity and recovery.

As researchers continue to explore this line of inquiry, it will be essential to investigate its potential applications in humans. While the results are encouraging, much work remains to be done before translating these findings into clinical practice. Nevertheless, the promise of a more effective treatment for ASD and related conditions is undeniable, offering hope for those affected by these disorders.

The intersection of brain science and therapeutic innovation continues to yield groundbreaking discoveries, challenging long-held assumptions about neurological development and recovery. As research advances, it becomes increasingly clear that our understanding of the brain’s resilience is still in its infancy.